Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Ulrika Ericson

Ulrika Ericson

Associate professor

Ulrika Ericson

Impaired functional vitamin B6 status is associated with increased risk of lung cancer

Author

  • Despoina Theofylaktopoulou
  • Øivind Midttun
  • Per M. Ueland
  • Klaus Meyer
  • Anouar Fanidi
  • Wei Zheng
  • Xiao Ou Shu
  • Yong Bing Xiang
  • Ross Prentice
  • Mary Pettinger
  • Cynthia A. Thomson
  • Graham G. Giles
  • Allison Hodge
  • Qiuyin Cai
  • William J. Blot
  • Jie Wu
  • Mikael Johansson
  • Johan Hultdin
  • Kjell Grankvist
  • Victoria L. Stevens
  • Marjorie M. McCullough
  • Stephanie J. Weinstein
  • Demetrius Albanes
  • Regina Ziegler
  • Neal D. Freedman
  • Arnulf Langhammer
  • Kristian Hveem
  • Marit Næss
  • Howard D. Sesso
  • J. Michael Gaziano
  • Julie E. Buring
  • I. Min Lee
  • Gianluca Severi
  • Xuehong Zhang
  • Meir J. Stampfer
  • Jiali Han
  • Stephanie A. Smith-Warner
  • Anne Zeleniuch-Jacquotte
  • Loic Le Marchand
  • Jian Min Yuan
  • Renwei Wang
  • Lesley M. Butler
  • Woon Puay Koh
  • Yu Tang Gao
  • Nathaniel Rothman
  • Ulrika Ericson
  • Emily Sonestedt
  • Kala Visvanathan
  • Miranda R. Jones
  • Caroline Relton
  • Paul Brennan
  • Mattias Johansson
  • Arve Ulvik

Summary, in English

Circulating vitamin B6 levels have been found to be inversely associated with lung cancer. Most studies have focused on the B6 form pyridoxal 5′-phosphate (PLP), a direct biomarker influenced by inflammation and other factors. Using a functional B6 marker allows further investigation of the potential role of vitamin B6 status in the pathogenesis of lung cancer. We prospectively evaluated the association of the functional marker of vitamin B6 status, the 3-hydroxykynurenine:xanthurenic acid (HK:XA) ratio, with risk of lung cancer in a nested case–control study consisting of 5,364 matched case–control pairs from the Lung Cancer Cohort Consortium (LC3). We used conditional logistic regression to evaluate the association between HK:XA and lung cancer, and random effect models to combine results from different cohorts and regions. High levels of HK:XA, indicating impaired functional B6 status, were associated with an increased risk of lung cancer, the odds ratio comparing the fourth and the first quartiles (OR4th vs. 1st) was 1.25 (95% confidence interval, 1.10–1.41). Stratified analyses indicated that this association was primarily driven by cases diagnosed with squamous cell carcinoma. Notably, the risk associated with HK:XA was approximately 50% higher in groups with a high relative frequency of squamous cell carcinoma, i.e., men, former and current smokers. This risk of squamous cell carcinoma was present in both men and women regardless of smoking status.

Department/s

  • Department of Clinical Sciences, Malmö
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year

2018-06-15

Language

English

Pages

2425-2434

Publication/Series

International Journal of Cancer

Volume

142

Issue

12

Document type

Journal article

Publisher

John Wiley and Sons

Topic

  • Cancer and Oncology

Keywords

  • 3-hydroxykynurenine:xanthurenic acid
  • functional vitamin B6 marker
  • Lung Cancer Cohort Consortium
  • pyridoxal 5′-phosphate

Status

Published

ISBN/ISSN/Other

  • ISSN: 0020-7136